.png)
.png)
.png)
.png)
.png)
.png)
Our Array Platforms
Methylation Screening Array (MSA)
- High-Throughput Capability: Supports up to 48 samples per BeadChip, facilitating large-scale studies.
- Focused Content: Includes probes associated with traits such as aging, environmental exposures, and metabolic diseases.
- Cost-Effective: Designed to provide comprehensive data at a reduced cost compared to broader arrays.
- Multi-Omic Integration: Incorporates content for CpH methylation and single nucleotide polymorphisms (SNPs), enriching the dataset for integrative analyses.
EPIC v2.0 Array
- Extensive Coverage: Targets over 99% of RefSeq genes, including promoter and enhancer regions.
- Enhanced Content: Includes additional probes for regions identified through ATAC-Seq and ChIP-Seq experiments.
- Advanced Analysis Tools: Compatible with bioinformatics tools like SeSAMe and minfi for data processing and analysis.
- Multi-Omic Integration: Incorporates content for CpH methylation and single nucleotide polymorphisms (SNPs), enriching the dataset for integrative analyses.
The EPIC v2.0 array delivers expanded enhancer coverage, reliable results across diverse ancestries, support for low-input DNA (~1 ng), and preserved coverage of key tools like epigenetic clocks and immune deconvolution panels.Additionally, we have run over 100,000 EPIC (V1.0 and V2.0) samples since our inception and have a full suite of algorithms trained on both platforms, including:
- 30+ biological age clocks
- 4 mitotic clocks
- 12- and 19-cell immune deconvolution
- 1,600+ Epigenetic Biomarker Proxies described here
- 100+ longitudinal intervention datasets
- Diagnostic and risk predictive Methylation Risk Scores (MRS) for 40+ different disease conditions
Xtra DNAm Array
- Comprehensive Coverage: Integrates content from MSA and EPIC v2.0 arrays with additional CoRSIV-targeted regions.
- Enhanced Phenotypic Relevance: CoRSIVs are associated with various human diseases, including obesity, cancer, and neurological disorders.
- High Phenotypic Relevance: CoRSIVs are approximately 50-100 times more phenotypically relevant than other regions, offering deeper insights into disease mechanisms.
CoRSIVs are genomic regions where DNA methylation patterns show consistent variation between individuals across different tissues. This makes them especially valuable for studies exploring the epigenetic basis of complex traits and diseases. Unlike most CpGs, CoRSIVs capture stable interindividual differences that are often more phenotypically informative.CoRSIVs are related to health outcomes more than any other region, making this array an excellent measure for biological health predictions. For instance, data has shown that these regions are 50-100x more phenotypically penetrant (equivalent to 1.5M-3M CpGs).
Imprintome Array
- Targeted Imprintome Coverage: Profiles ~200 known and predicted imprinted regions, including maternal and paternal allele-specific methylation zones.
- Designed for Disease-Relevant Discovery: Ideal for studying disorders of imprinting, developmental syndromes, aging, and transgenerational epigenetic inheritance.
- High-CpG Density Per Region: Each region contains multiple CpG sites (typically 3-15), providing robust statistical power and methylation state clarity.
- Cross-Compatible with Multi-Omic Pipelines: Designed for seamless integration with transcriptomics, proteomics, and single-cell methylation tools.
Imprinted genes are uniquely susceptible to epigenetic dysregulation. Unlike other loci, they are monoallelically expressed, meaning they rely on precise methylation signals from only one parental chromosome. When these signals go awry, the resulting phenotypes can be severe and systemic.Unlike most DNA methylation CpGs, these behave more like genetics with consistency among tissues and throughout time.To address the growing need for precise methylation profiling in these regions, we developed the Imprintome array, the world’s first commercially available DNA methylation array focused exclusively on imprinting control regions, in combination with researchers from North Carolina State University.
